Drug-eluting wound dressings having sustained release of antimicrobial compounds
Copyright © 2020 Elsevier B.V. All rights reserved..
Wound healing is a complex and costly public health problem that should be timely addressed to achieve a rapid and adequate tissue repair avoiding or even eliminating potential pathogenic infection. Chronic infected non-healing wounds represent a serious concern for health care systems. Efficient wound dressings with tailored therapy having the best response and highest safety margin for the management of chronic non-healing wounds are still needed. The use of novel wound dressing materials has emerged as a promising tool to fulfil these requirements. In this work, asymmetric electrospun polycaprolactone (PCL)-based nanofibers (NFs) were decorated with electrosprayed poly(lactic-co-glycolic acid) microparticles (PLGA MPs) containing the natural antibacterial compound thymol (THY) in order to obtain drug eluting antimicrobial dressings having sustained release. The synthesized dressings successfully inhibited the in vitro growth of Staphylococcus aureus ATCC 25923, showing also at the same doses cytocompatibility on human dermal fibroblasts and keratinocyte cultures after treatment for 24 h, which was not observed when using free thymol. An in vivo murine excisional wound splinting model, followed by the experimental infection of the wounds with S. aureus and their treatment with the synthesized dressings, pointed to the reduction of the bacterial load in wounds after 7 days, though the total elimination of the infection was not reached. The findings indicated the relevance of the direct contact between the dressings and the bacteria, highlighting the need to tune their design considering the wound surface and the nature of the antimicrobial cargo contained.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:152 |
|---|---|
| Enthalten in: |
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V - 152(2020) vom: 15. Juli, Seite 327-339 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gámez-Herrera, Enrique [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 05.02.2021 Date Revised 05.02.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ejpb.2020.05.025 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM310537460 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM310537460 | ||
| 003 | DE-627 | ||
| 005 | 20231225140319.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejpb.2020.05.025 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1035.xml |
| 035 | |a (DE-627)NLM310537460 | ||
| 035 | |a (NLM)32473289 | ||
| 035 | |a (PII)S0939-6411(20)30152-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gámez-Herrera, Enrique |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Drug-eluting wound dressings having sustained release of antimicrobial compounds |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.02.2021 | ||
| 500 | |a Date Revised 05.02.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier B.V. All rights reserved. | ||
| 520 | |a Wound healing is a complex and costly public health problem that should be timely addressed to achieve a rapid and adequate tissue repair avoiding or even eliminating potential pathogenic infection. Chronic infected non-healing wounds represent a serious concern for health care systems. Efficient wound dressings with tailored therapy having the best response and highest safety margin for the management of chronic non-healing wounds are still needed. The use of novel wound dressing materials has emerged as a promising tool to fulfil these requirements. In this work, asymmetric electrospun polycaprolactone (PCL)-based nanofibers (NFs) were decorated with electrosprayed poly(lactic-co-glycolic acid) microparticles (PLGA MPs) containing the natural antibacterial compound thymol (THY) in order to obtain drug eluting antimicrobial dressings having sustained release. The synthesized dressings successfully inhibited the in vitro growth of Staphylococcus aureus ATCC 25923, showing also at the same doses cytocompatibility on human dermal fibroblasts and keratinocyte cultures after treatment for 24 h, which was not observed when using free thymol. An in vivo murine excisional wound splinting model, followed by the experimental infection of the wounds with S. aureus and their treatment with the synthesized dressings, pointed to the reduction of the bacterial load in wounds after 7 days, though the total elimination of the infection was not reached. The findings indicated the relevance of the direct contact between the dressings and the bacteria, highlighting the need to tune their design considering the wound surface and the nature of the antimicrobial cargo contained | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Antibacterial nanomaterials | |
| 650 | 4 | |a Dressing | |
| 650 | 4 | |a Electrospinning | |
| 650 | 4 | |a In vivo murine model | |
| 650 | 4 | |a Non-healing wounds | |
| 650 | 4 | |a Thymol | |
| 650 | 4 | |a Wound infection | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Delayed-Action Preparations |2 NLM | |
| 650 | 7 | |a Polyesters |2 NLM | |
| 650 | 7 | |a polycaprolactone |2 NLM | |
| 650 | 7 | |a 24980-41-4 |2 NLM | |
| 650 | 7 | |a Thymol |2 NLM | |
| 650 | 7 | |a 3J50XA376E |2 NLM | |
| 700 | 1 | |a García-Salinas, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Salido, Sofía |e verfasserin |4 aut | |
| 700 | 1 | |a Sancho-Albero, María |e verfasserin |4 aut | |
| 700 | 1 | |a Andreu, Vanesa |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Luján, Lluís |e verfasserin |4 aut | |
| 700 | 1 | |a Irusta, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Arruebo, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Mendoza, Gracia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V |d 1997 |g 152(2020) vom: 15. Juli, Seite 327-339 |w (DE-627)NLM090658442 |x 1873-3441 |7 nnns |
| 773 | 1 | 8 | |g volume:152 |g year:2020 |g day:15 |g month:07 |g pages:327-339 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejpb.2020.05.025 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 152 |j 2020 |b 15 |c 07 |h 327-339 | ||